AAAAAA
Results: 1-25/50
Authors:
TETREAULT S
ABLER SL
ROBBINS B
SAVEN A
Citation: S. Tetreault et al., PERIPHERAL T-CELL LYMPHOMA AFTER ANTI-CD20 ANTIBODY THERAPY, Journal of clinical oncology, 16(4), 1998, pp. 1635-1636
Authors:
PAULS JD
BREMS J
POCKROS PJ
SAVEN A
WAGNER RL
WEBER R
METCALFE DD
CHRISTIANSEN SC
Citation: Jd. Pauls et al., MASTOCYTOSIS - DIVERSE PRESENTATIONS AND OUTCOMES, Journal of allergy and clinical immunology, 101(1), 1998, pp. 892-892
Authors:
SAVEN A
BURIAN C
KOZIOL JA
PIRO LD
Citation: A. Saven et al., LONG-TERM FOLLOW-UP OF PATIENTS WITH HAIRY-CELL LEUKEMIA AFTER CLADRIBINE TREATMENT, Blood, 92(6), 1998, pp. 1918-1926
Authors:
GOLLARD R
MILLER WE
PIRO LD
SAVEN A
Citation: R. Gollard et al., 2-CHLORODEOXYADENOSINE ADMINISTRATION TO PATIENTS WITH THE MYELOID BLAST PHASE OF CHRONIC MYELOGENOUS LEUKEMIA, Leukemia & lymphoma, 28(1-2), 1997, pp. 183-185
Authors:
WHITE CA
GRILLOLOPEZ AJ
MALONEY D
BODKIN D
CZUCZMAN M
MCLAUGHLIN P
CABANILLAS F
SAVEN A
SALEH M
Citation: Ca. White et al., REVIEW OF SINGLE-AGENT IDEC-C2B8 SAFETY AND EFFICACY RESULTS IN LOW-GRADE OR FOLLICULAR NON-HODGKINS-LYMPHOMA (NHL), European journal of cancer, 33, 1997, pp. 91-91
Authors:
MEISENBERG BR
MILLER WE
MCMILLAN R
CALLAGHAN M
SLOAN C
BREHM T
KOSTY MP
KROENER J
LONGMIRE R
SAVEN A
PIRO LD
Citation: Br. Meisenberg et al., OUTPATIENT HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE FOR HEMATOLOGIC AND NONHEMATOLOGIC MALIGNANCIES, Journal of clinical oncology, 15(1), 1997, pp. 11-17
Authors:
SAVEN A
LEE T
SCHLUTZ M
JACOBS A
ELLISON D
LONGMIRE R
PIRO L
Citation: A. Saven et al., MAJOR ACTIVITY OF CLADRIBINE IN PATIENTS WITH DE-NOVO B-CELL PROLYMPHOCYTIC LEUKEMIA, Journal of clinical oncology, 15(1), 1997, pp. 37-43
Authors:
SAVEN A
Citation: A. Saven, PURINE ANALOGS FOR TREATMENT OF REFRACTORY ESSENTIAL MIXED CRYOGLOBULINEMIA - RESPONSE, Mayo Clinic proceedings, 72(1), 1997, pp. 93-93
Authors:
WEBER R
MARTINEZ D
COLWELL C
WALKER R
BYLUND D
GRIFFIN J
SAVEN A
Citation: R. Weber et al., ACTIVATED PROTEIN-C RESISTANCE IN PATIENTS WITH VENOUS THROMBOEMBOLISM FOLLOWING TOTAL JOINT REPLACEMENT, Blood, 90(10), 1997, pp. 3275-3275
Authors:
RAJA N
MILLER WE
MCMILLAN R
KOSTY MP
SAVEN A
MEISENBERG BR
MASON JR
Citation: N. Raja et al., TANDEM CYCLES OF HIGH-DOSE CHEMOTHERAPY (HDC) WITH PERIPHERAL-BLOOD PROGENITOR-CELL RESCUE (PBPCR) FOR PATIENTS WITH RELAPSED OR HIGH-RISK LYMPHOMA, Blood, 90(10), 1997, pp. 4576-4576
Authors:
LIU E
BURIAN C
MILLER W
SAVEN A
Citation: E. Liu et al., BOLUS ADMINISTRATION OF CLADRIBINE IN THE TREATMENT OF WALDENSTROM MACROGLOBULINEMIA (WM), Blood, 90(10), 1997, pp. 1537-1537
Authors:
SAVEN A
BURIAN C
KOZIOL J
PIRO L
Citation: A. Saven et al., LONG-TERM FOLLOW-UP OF PATIENTS WITH HAIRY-CELL LEUKEMIA (HCL) FOLLOWING CLADRIBINE TREATMENT, Blood, 90(10), 1997, pp. 2573-2573
Authors:
SAVEN A
PIRO LD
Citation: A. Saven et Ld. Piro, 2-CHLORODEOXYADENOSINE - A POTENT ANTIMETABOLITE WITH MAJOR ACTIVITY IN THE TREATMENT OF INDOLENT LYMPHOPROLIFERATIVE DISORDERS, HEM CELL TH, 38, 1996, pp. 93-101
Authors:
GOODMAN MG
SPINOSA JC
SAVEN A
PIRO LD
WORMSLEY S
Citation: Mg. Goodman et al., NEW PERSPECTIVES ON THE APPROACH TO CHRONIC LYMPHOCYTIC-LEUKEMIA, Leukemia & lymphoma, 22(1-2), 1996, pp. 1-10
Authors:
SAVEN A
LEE T
KOSTY M
PIRO L
Citation: A. Saven et al., CLADRIBINE AND MITOXANTRONE DOSE-ESCALATION IN INDOLENT NON-HODGKINS-LYMPHOMA, Journal of clinical oncology, 14(7), 1996, pp. 2139-2144
Authors:
SAVEN A
CHEUNG WK
SMITH I
MOYER M
JOHANNSEN T
ROSE E
GOLLARD R
KOSTY M
MILLER WE
PIRO LD
Citation: A. Saven et al., PHARMACOKINETIC STUDY OF ORAL AND BOLUS INTRAVENOUS 2-CHLORODEOXYADENOSINE IN PATIENTS WITH MALIGNANCY, Journal of clinical oncology, 14(3), 1996, pp. 978-983
Authors:
POCKROS PJ
YOUNOSSI ZM
WILKES LB
SAVEN A
Citation: Pj. Pockros et al., AN OPEN-LABEL PILOT-STUDY OF 2-CHLORODEOXYADENOSINE (2-CDA) IN THE TREATMENT OF EARLY-STAGE PRIMARY SCLEROSING CHOLANGITIS (PSC), Hepatology, 24(4), 1996, pp. 174-174
Authors:
SAVEN A
Citation: A. Saven, FLUDARABINE TREATMENT AND TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE, Lancet, 348(9025), 1996, pp. 473-473
Authors:
SAVEN A
Citation: A. Saven, THE SCRIPPS-CLINIC EXPERIENCE WITH CLADRIBINE (2-CDA) IN THE TREATMENT OF CHRONIC LYMPHOCYTIC-LEUKEMIA, Seminars in hematology, 33(1), 1996, pp. 28-33
Authors:
LEE TC
MILLER WE
CURD JG
PIRO LD
SAVEN A
Citation: Tc. Lee et al., PROLONGED, COMPLETE REMISSION AFTER 2-CHLORODEOXYADENOSINE THERAPY INA PATIENT WITH REFRACTORY ESSENTIAL MIXED CRYOGLOBULINEMIA, Mayo Clinic proceedings, 71(10), 1996, pp. 966-968
ACUTE MYELOGENOUS LEUKEMIA PRESENTING WITH BULKY LYMPHADENOPATHY - CASE-REPORT AND LITERATURE-REVIEW
Authors:
GOLLARD RP
ROBBINS BA
PIRO L
SAVEN A
Citation: Rp. Gollard et al., ACUTE MYELOGENOUS LEUKEMIA PRESENTING WITH BULKY LYMPHADENOPATHY - CASE-REPORT AND LITERATURE-REVIEW, Acta haematologica, 95(2), 1996, pp. 129-134
Authors:
SAVEN A
LEMON RH
KOSTY M
BEUTLER E
PIRO LD
Citation: A. Saven et al., 2-CHLORODEOXYADENOSINE ACTIVITY IN PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC-LEUKEMIA, Journal of clinical oncology, 13(3), 1995, pp. 570-574
Authors:
GOLLARD R
LEE TC
PIRO LD
SAVEN A
Citation: R. Gollard et al., THE OPTIMAL MANAGEMENT OF HAIRY-CELL LEUKEMIA, Drugs, 49(6), 1995, pp. 921-931
Authors:
SAVEN A
EMANUELE S
KOSTY M
KOZIOL J
ELLISON D
PIRO L
Citation: A. Saven et al., 2-CHLORODEOXYADENOSINE ACTIVITY IN PATIENTS WITH UNTREATED, INDOLENT NON-HODGKINS-LYMPHOMA, Blood, 86(5), 1995, pp. 1710-1716
Authors:
PIRO LD
PETRONI G
BARCOS M
JOHNSON J
SAVEN A
PETERSON B
Citation: Ld. Piro et al., BOLUS INFUSION 2-CHLORODEOXYADENOSINE (2-CDA) AS FIRST-LINE THERAPY OF LOW-GRADE NON-HODGKINS-LYMPHOMA (NHL) - CALGB-9153, Blood, 86(10), 1995, pp. 1082-1082